Post Treatment Care After Chemical Peel or Laser Resurfacing

NCT01135290 | Withdrawn Early Phase 1

• 1 other identifier: 828-101-09-016
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

This study tests two different approaches to the resolution of facial skin resurfacing.

Conditions

Chemical Peel

Keywords

The management of post-treatment symptoms for subjects that had either a medium grade chemical peel or fractional resurfacing

Outcome Measures

Primary Outcomes (1)

• Physician and subject evaluation ratings of the signs and symptoms of facial skin during post-operative care.

  84 Days

Study Arms (2)

B

OTHER

Drug: Aquaphor

A

ACTIVE COMPARATOR

Drug: HP828-101

Interventions

Aquaphor DRUG

B

HP828-101 DRUG

A

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The informed consent document and photography release must be read, signed, and dated by the subject or the subject's legally authorized representative before conducting any study procedures or exams. In addition, the informed consent and photography release document must be signed and dated by the individual who consents the subject before conducting Visit 1. A photocopy of the signed informed consent document must be provided to the subject, and the original signed document placed in the subject's chart.
• Subjects 18 years of age or older, scheduled to undergo either a medium chemical peel with 35% TCA or a laser resurfacing. Subjects may be of either sex and of any race or skin type provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments.
• Women of child-bearing potential (those who are not premenarchal, not surgically sterilized \[hysterectomy or bilateral oophorectomy\], or not post-menopausal) may participate in the study if they meet all of the following conditions:
• they are not breast feeding
• undertake a pregnancy test, which must be negative
• they do not intend to become pregnant during the study
• they are using adequate birth control methods and they agree to continue using those methods for the duration of the study
• Adequate birth control methods are defined as: hormonal-topical, oral, implantable, or injectable contraceptives; mechanical-spermicide in conjunction with a barrier such as a condom or diaphragm; IUD; or, surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use an adequate birth control method as described above for the remainder of the study.
• NOTE: Women who have had a bilateral tubal ligation are not considered to have been surgically sterilized and must agree to the conditions as specified above.
• Willing and able to make all required study visits.
• Able to follow instructions.
• Undergo a medium grade chemical peel or fractional resurfacing.

You may not qualify if:

• Contraindications or hypersensitivity to the use of the study medications or their components (e.g., balsam of Peru, castor oil, or phenoxyethanol).
• Therapy with another investigational agent within thirty (30) days of Visit 1, or during the study.
• Have taken anticoagulants (blood thinners, including aspirin) within two weeks.
• Current smoker.
• Use of oral isotretinoin during the past 12 months, systemic steroids, topical retinoids, or topical corticosteroids within the month prior to the study.
• Have any congenital skin disorder which affects keratinocytes, elastin, or collagen.
• Have any dermatologic disease which may be aggravated or provoked by the wounding procedure.
• Are at risk of keloid or hypertrophic scar formation based on personal or family history, or skin exam.
• Have any skin disorder which causes delayed healing.
• Have any systemic condition that would compromise skin healing.
• The Medical Monitor may declare any subject ineligible for a valid medical reason.

Sponsors & Collaborators

• Healthpoint: lead

Study Sites (1)

University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States

Location

MeSH Terms

Interventions

Petrolatum

Intervention Hierarchy (Ancestors)

Hydrocarbons; Organic Chemicals

Study Officials

• Herbert B Slade, MD

  Healthpoint

  STUDY CHAIR

• Jeffery Kenkel, MD

  University of Texas Southwestern Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: CARE PROVIDER
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: June 1, 2010
• First Posted: June 2, 2010
• Study Start: June 1, 2010
• Primary Completion: October 1, 2010
• Study Completion: October 1, 2010
• Last Updated: October 1, 2013

Record last verified: 2013-09

Locations

US (1)